SCHEMBL21713810

SCHEMBL21713810

O=C(O)N1CCC1CNS(=O)(=O)c1cccnc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.42
TSHR P16473 1/20 0.42
ALDH1A1 P00352 5/20 0.41
MAPT P10636 2/20 0.41
CNR2 P34972 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
ACLY P53396 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
RECQL P46063 2/20 0.38
POLB P06746 1/20 0.38
DPP4 P27487 3/20 0.38
CHRM1 P11229 2/20 0.37
LDHA P00338 1/20 0.37
DPP8 Q6V1X1 1/20 0.36
DPP9 Q86TI2 1/20 0.36
DPP7 Q9UHL4 1/20 0.36
MEN1 O00255 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21714012 0.93 DPP4 (0.45) HPGDTSHRALDH1A1MAPTCNR2
SCHEMBL21714141 0.92 HPGD (0.45) HPGDTSHRALDH1A1MAPTCNR2
SCHEMBL21713456 0.86 CNR2 (0.42) HPGDTSHRALDH1A1MAPTCNR2
SCHEMBL21713798 0.85 POLB (0.46) HPGDTSHRALDH1A1MAPTCNR2
SCHEMBL21713313 0.84 HCRTR1 (0.43) HPGDTSHRALDH1A1MAPTCNR2
SCHEMBL21714047 0.79 KDM1A (0.47) HPGDTSHRALDH1A1MAPTLMNA
SCHEMBL29819176 0.79 KDM1A (0.47) HPGDTSHRALDH1A1MAPTLMNA
SCHEMBL21713983 0.76 DPP4 (0.44) ALDH1A1DPP4DPP8DPP9DPP7
SCHEMBL21713410 0.76 DPP4 (0.44) ALDH1A1DPP4DPP8DPP9DPP7
SCHEMBL21713889 0.75 DPP4 (0.42) HPGDTSHRALDH1A1DPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4364804-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION Janssen Pharmaceutica NV (BE) 2024-05-08 EP disclosed
US-11897900-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction JANSSEN PHARMACEUTICA NV (BE) 2024-02-13 US disclosed
EP-3833662-B1 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2024-01-17 EP disclosed
EP-3833662-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION Janssen Pharmaceutica N.V. (BE) 2021-06-16 EP disclosed
US-10947252-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction JANSSEN PHARMACEUTICA NV (BE) 2021-03-16 US disclosed
WO-2020041169-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2020-02-27 WO disclosed
US-20200055874-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2020-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11897900-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction KEAP1, NFE2L2, HMOX1 HPGD 152/4885TSHR 4787/4885ALDH1A1 1271/4885
US-20200055874-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION KEAP1, NFE2L2, HMOX1 HPGD 152/4885TSHR 4787/4885ALDH1A1 1271/4885
US-10947252-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction KEAP1, NFE2L2, HMOX1 HPGD 152/4885TSHR 4787/4885ALDH1A1 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.